Dear all,
To answer directly to the question of capripoxvirus recombinant vaccine
approach developed by CIRAD, we have generated H-PPR and F-PPR
recombinant capripoxviruses that protect against both diseases. We also
generated recombinant Rift Valley fever-capripoxvirus that is
imunologically active (no challenge studies so far). We are thinking
about a trivalent vaccine, for instance PPR-Rift-capripoxvirus.
The advantages of the capripoxvirus in our hands are:
- easy platform to insert and express in target animals several
different transgenes (e.g.: a perfectly characterized immunogen of
Brucella could be inserted and tested)
- long lasting immunity after one shoot (at least one year of protection)
- DIVA property for the diseases targeted by the inserts (in the case of
PPR, we induce anti-H or anti-F immune responses and we test the serum
anti-N antibodies by a commercial ELISA)
- thermal stability (2 weeks in liquid form at +36°C)
However, the current drawbacks are:
- validations are still required before use in the field: purity check
(possibly by deep sequencing without a priori), upscaling of the
production, etc... (according to the requirements of the private
industry and international regulations)
- pre-immunity interference with the vaccine: first vaccination with
this type of vaccine in a ruminant population infected by wild-type
capripoxvirus may not protect more than 50% of the animals against pox
_AND_ PPR. This means that the first year, a combination of recombinant
capripox and Nigeria75/1 vaccine [a paper in Vaccine (Chaudary et al,
2009) showed that both vaccines could be combined in a single injection]
should be applied to reduce the prevalence of capripoxvirus and then the
next year, only the recombinant capripoxvirus could be used
- Lack of funds to speed up finalization of laboratory work before
transfer of the vaccine to the private sector
Regards
For CIRAD, Emmanuel Albina
Le 25/02/2014 12:19, Paul Rossiter a écrit :
> Dear moderator and dear all,
> I agree with that we should include other diseases such as sheep and
> goats pox in the progressive control of PPR in small ruminants. If I
> well remember Cirad had in collaboration with LANAVET
> (Cameroon) developped recombinant vaccine against PPR using Capripox
> as support. I don't know if this vaccine is still available ; if yes
> so we can easily go for progressive control of PPR and SGP. I think Dr
> Adama or Ngagnou could answer to this.
> Kind regards!
> Bidjeh Kebkiba,
> Head of virology Unit, IRED (Chad),
> Route de farcha,
> PO box 433, Ndjamena- Chad.
>
> ------------------------------------------------------------------------
>
> To unsubscribe from the FAO-AnimalHealth-L list, click the following link:
> https://listserv.fao.org/cgi-bin/wa?SUBED1=FAO-AnimalHealth-L&A=1
>
--
Signature electronique
########################################################################
To unsubscribe from the FAO-AnimalHealth-L list, click the following link:
https://listserv.fao.org/cgi-bin/wa?SUBED1=FAO-AnimalHealth-L&A=1
|